An Intermediate Size Expanded Access Protocol of AMX0035 for ALS

Intermediate Expanded Access Protocol CNMAu8.EAP04

NCT06408727 ·Status: TEMPORARILY_NOT_AVAILABLE

Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and CNMAu8.EAP02 for ALS

NCT05281484 ·Status: NO_LONGER_AVAILABLE

Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)

NCT04569435 ·Status: COMPLETED ·Phase: PHASE2

Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis

NCT01492686 ·Status: COMPLETED ·Phase: PHASE3

FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)

NCT04768972 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

NCT06100276 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

NCT00330681 ·Status: COMPLETED ·Phase: PHASE3

Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS)

NCT01142856 ·Status: COMPLETED ·Phase: PHASE1

Intermediate-size Patient Population Expanded Access Protocol

NCT07088159 ·Status: AVAILABLE

Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)

NCT03268603 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Safety/Efficacy Study for the Treatment of Amyotrophic Lateral Sclerosis

NCT01082653 ·Status: SUSPENDED ·Phase: PHASE1

Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy

NCT05542576 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis

NCT00355576 ·Status: COMPLETED ·Phase: PHASE2

MRG-001 in Patients With Amyotrophic Lateral Sclerosis

NCT06315608 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)

NCT01091142 ·Status: COMPLETED ·Phase: PHASE1

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intrathecal Injection for ALS

NCT05003921 ·Status: SUSPENDED ·Phase: PHASE1

Phase1 First in Human Ascending Dose Study to Evaluate the Safety and Tolerability of FC-12738 in Health Adults

NCT05978908 ·Status: COMPLETED ·Phase: PHASE1

First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)

NCT06351592 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS

NCT05349721 ·Status: TERMINATED ·Phase: PHASE2

Biological Treatment of Amyotrophic Lateral Sclerosis

NCT02193893 ·Status: UNKNOWN ·Phase: PHASE1

A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS

NCT05279755 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT03537807 ·Status: NO_LONGER_AVAILABLE

A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT06441682 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS

NCT00868166 ·Status: COMPLETED ·Phase: PHASE3

A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS

NCT05357950 ·Status: COMPLETED ·Phase: PHASE2